Company Overview and News
Japan's Nikkei share average rose on Friday morning after the European Central Bank announced it would avoid raising rates until mid-2019, but chip-related stocks tumbled after a brokerage slashed the target price of Tokyo Electron.
4503 ALPMY ADTTF ALPMF MRAAF MRAAY 8035 TOELF ATEYY TOELY
The semiconductor industry has been red hot this year, up 16.5% as a whole versus 4% for the S&P 500. Top industry players like Micron Technology (MU - Free Report) and Nvidia (NVDA - Free Report) have gotten the lion’s share of the attention from investors – and rightfully so as they have performed even better than the industry.
HD CREE MU VSH CSX NVDA 8035 TOELF YY TOELY
The 225-issue Nikkei average lost 227.77 points, or 0.99 percent, to close at 22,738.61 on the Tokyo Stock Exchange. On Wednesday, the key market gauge rose 88.03 points.
8035 TOELF TOELY
A company’s ability to provide good returns to its investors even after meeting all its business-related costs and expenses can be measured using profitability analysis. A fundamentally strong company generally has a high level of profitability. In this respect, we have used an accounting ratio to evaluate the profitability position of a company and identify a profitable company over a loss-making one.
ALGN AAWW XOM SEDG MOMO 8035 TOELF TOELY
Lam Research recognized billings of more than $1 billion in April from memory customers, which added to the company's $2.6 billion in billings for memory customers in FY Q3.
LRCX SSNLF HXSCF BC94 SMSN TOELY MU AMAT INTC 8035 TOELF HXSCL SMSD
The 225-issue Nikkei average gained 74.31 points, or 0.33 percent, to end at 22,878.35 on the Tokyo Stock Exchange. On Monday, the key market gauge climbed 109.54 points.
9020 8035 TOELF TOELY
Memory chip companies' semiconductor spend in 2017 grew 68% from 2016, which will result in capacity increases of 45% by the end of 2018.
LRCX SSNLF HXSCF MS.PRE MS.PRF MS.PRG MS.PRA TOELY MS.PRI MU MS.PRK AMAT MS 8035 TOELF HXSCL
TOKYO (Reuters) - Japan’s Nikkei share average rose to a one-week high on Monday morning, tracking Friday’s Wall Street’s gains after May jobs data pointed to strength in the U.S. economy, while a weaker yen lifted shares of Japanese exporters.
TM TYT TOYOF TOELY 25935 NDAQ TTDKF ITOEF 7203 ITONF 8035 TOELF 2593
Tokyo's benchmark Nikkei index rose Monday as geopolitical worries ebbed after US and North Korean officials met to resume preparations for a summit between the leaders of the two countries.
8035 TOELF TOELY
The benchmark Nikkei average edged up on the Tokyo Stock Exchange on Monday, with many investors refraining from active trading amid a dearth of fresh trading incentives.
JAPSY 8035 TOELF TOELY
3h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET